All In MedTech

Device Trial Radar · NCT02009982

Cardioneuroablation for Neurocardiogenic Syncope

Last checked: Nov 20, 2026Latest source record: Nov 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

3

Actual

Start

Dec 2013

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
David B. De LurgioAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Biosense Webster, Inc.
First posted
Dec 12, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness of cardioneuroablation for the treatment of neurocardiogenic syncope (NCS), also known as "vaso-vagal" syncope. Syncope is a general term for passing out spells and neurocardiogenic syncope is a specific form of passing out spells caused by sudden drops in heart rate or blood pressure. Although the specific mechanisms of NCS are not well understood, it is believed that some people are prone to developing passing out spells in specific situations such as standing up for a long period of time, pain or nausea. In these situations, the body reacts with a paradoxical reflex which leads to a drop in blood pressure and heart rate and causes passing out. Certain types of medications are used to treat NCS including beta-blockers, midodrine and florinef, among others. However, none of these medications are particularly effective at preventing passing out spells and many people continue to have episodes despite trying different medications. Cardioneuroablation is a new form of treatment for NCS. The term ablation means using a wire to make small electrical burns in the heart. Ablation has been used for many years to treat other electrical disturbances in the heart but the use of ablation to treat NCS is a new application. The goal of cardioneuroablation is to identify areas within the heart which are believed to initiate the reflex which triggers the drop in heart rate and blood pressure that leads to passing out. In preliminary studies, it has been suggested that cardioneuroablation may be significantly more effective than medications at preventing passing out spells for people with NCS. Hypothesis: Cardioneuroablation of vagal inputs in the left atrium may serve as an effective treatment modality for the prevention of NCS by blunting the initial trigger of the cascade that leads to symptoms and syncope.

Conditions

  • Neurocardiogenic Syncope
  • Vasovagal Syncope

Interventions

  • CardioneuroablationProcedure

    Catheter Ablation of Vagal Inputs in Left Atrium

  • Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip CatheterDevice

    This is the device that will be used to perform the Cardioneuroablation procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Syncope Recurrence RateTime frame: 12 Months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Emory University

    Atlanta, Georgia

  • University of North Carolina

    Chapel Hill, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.